Reliq Health Technologies Inc.

SADIF Investment Analytics (5/25/23) "RHT has a bright prospect, fair financials and good earnings quality."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (4/24/23) "AGN's stock is silly cheap and so a good investment."

Reliq Health Technologies Inc.

SADIF Investment Analytics (4/3/23) "RHT's stock has been upgraded to Above Average from Average."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (1/27/23) "Updates on Alzheimer's by three biopharmas are pertinent to PMN."

Reliq Health Technologies Inc.

Jefferson Research (1/20/23) "RHT's balance sheet rating improved during Q1/23."

Algernon Pharmaceuticals Inc.

Dr. Douglas Loe, Leede Jones Gable (1/13/23) "AGN plans to initiate a Phase 2b trial of ifenprodil in chronic cough."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (1/6/23) "We expect PMN to commence formal Phase 1 testing later this year."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (12/21/22) "When AGN moves, it is likely to result in big percentage gains."

Reliq Health Technologies Inc.

Jefferson Research (12/15/22) "The valuation for RHT suggests a lower amount of price risk."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (12/1/22) "Data presented by peers at the CTAD conference are relevant to PMN."

Algernon Pharmaceuticals Inc.

Dr. Andre Uddin, Research Capital Corporation (11/30/22) "Positive Phase 2a data were achieved with AGN's ifenprodil."

Reliq Health Technologies Inc.

Clive Maund, CliveMaund.com (11/22/22) "This is a good point to add to positions or make new purchases of RHQ."

Dr. Douglas Loe, Leede Jones Gable (11/4/22) "RHT added 50 new nursing home clients in Florida to its network."

Clive Maund, CliveMaund.com (11/1/22) "The dip of recent days presents us with a better entry point for RHT."

ProMIS Neurosciences Inc.

Steve Silver, Argus Research (10/28/22) "PMN expects to file an NDA for PMN310 with the FDA by 2022E."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (10/24/22) "AGN is rated a Buy again here."

Clive Maund, CliveMaund.com (10/16/22) "AGN is rated an immediate Strong Buy."

ProMIS Neurosciences Inc.

Clive Maund, CliveMaund.com (10/10/22) "This is a good time to buy PMN stock."

Dr. Douglas Loe, Leede Jones Gable (9/30/22) "PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."

Dr. Douglas Loe, Leede Jones Gable (9/28/22) "We are positive about PMN's PMN-310 possibly mitigating AD progression."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (9/27/22) "A minor relief rally in the broad market could see AGN shoot up again."

Awakn Life Sciences Corp.

Clive Maund, CliveMaund.com (9/11/22) "AWKNF's exceptionally positive technical setup keeps getting better."

Clive Maund, CliveMaund.com (9/5/22) "AWKNF is a stock that it is thought to be worth going overweight on."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (8/23/22) "The case for buying AGN here could scarcely be stronger."

Clive Maund, CliveMaund.com (8/17/22) "AGN is rated Buy again here."

Awakn Life Sciences Corp.

Clive Maund, CliveMaund.com (8/16/22) "AWKN is now in position to break out into a new bull market."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (8/15/22) "AGN has the capacity to make really big moves."

Awakn Life Sciences Corp.

Andrew Partheniou, Stifel (8/15/22) "AWKN announced its first KARE licensing agreement."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (8/5/22) "Experiments showed that PMN's PMN310 has a unique binding profile."

Algernon Pharmaceuticals Inc.

Dr. Andre Uddin, Research Capital Corporation (7/28/22) "It would be logical for AGN to develop ifenprodil for two indications."

Clive Maund, CliveMaund.com (7/28/22) "AGN is considered to be at another good buy spot here."

Dr. Andre Uddin, Research Capital Corporation (7/18/22) "In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

Reliq Health Technologies Inc.

Jefferson Research (7/14/22) "RHT's quality of net income earnings is extremely high."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (7/6/22) "PMN's PMN310 could benefit from favorable FDA review of lecanemab."

Steve Silver, Argus Research (7/6/22) "PMN designated PMN267 as its lead candidate for treatment of ALS."

Awakn Life Sciences Corp.

Patrick Trucchio, H.C. Wainwright & Co. (6/30/22) "AWKNF's key programs are on track."

ProMIS Neurosciences Inc.

Steve Silver, Argus Research (6/27/22) "PMN's PMN310 potentially represents a best-in-class opportunity."

Reliq Health Technologies Inc.

Jefferson Research (6/10/22) "RHT is showing strong earnings quality and cash flow quality."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (6/3/22) "VIV has signed a new distribution agreement with Nong San Viet Co."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (6/1/22) "AGN looks like it is shaping up for a breakout into a new bull market."

ProMIS Neurosciences Inc.

Dr. Douglas Loe, Leede Jones Gable (5/11/22) "We are initiating coverage on PMN with a Speculative Buy rating."

Awakn Life Sciences Corp.

Patrick Trucchio, H.C. Wainwright & Co. (5/2/22) "AWKNF's KARE program is on track to advance to Phase 3 in H2/22."

Reliq Health Technologies Inc.

Clive Maund, CliveMaund.com (4/26/22) "RHT is rated an Immediate Buy here."

ProMIS Neurosciences Inc.

Steve Silver, Argus Research (4/13/22) "We view PMN's path to clinical value inflection favorably."

Awakn Life Sciences Corp.

Andrew Partheniou, Stifel (3/31/22) "AWKNF shares offer an attractive risk-reward profile."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (2/2/22) "AGN has reacted back satisfactorily to another good buy spot."

Awakn Life Sciences Corp.

Patrick Trucchio, H.C. Wainwright & Co. (2/1/22) "AWKNF's R&D is focused on advancing therapies to treat addictions."

Avivagen Inc.

David Bautz, Zacks Small-Cap Research (1/31/22) "Sales of VIV's OxC-beta should begin to increase throughout 2022."

Algernon Pharmaceuticals Inc.

Dr. Andre Uddin, Research Capital Corporation (1/28/22) "AGN's current valuation is favorable from a risk-reward standpoint."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (1/27/22) "VIV is at an inflection point with sales increases around the corner."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (1/19/22) "As we can see on its latest six-month chart, AGN's stock has soared."

Bob Moriarty, 321 Gold (1/18/22) "AGN has a lot of potential, and I placed my bet with shares bought."

Stem Holdings Inc.

Joseph Gomes, Noble Capital Markets (1/18/22) "STEM reported net FY21 revenue of $35.8M versus $14M last year."

Algernon Pharmaceuticals Inc.

Clive Maund, CliveMaund.com (1/12/22) "After a 1 for 100 rollback, AGN has big upside potential."

Clive Maund, CliveMaund.com (12/22/21) "AGN stock looks like it is in the process of turning up from a low."

Clive Maund, CliveMaund.com (12/12/21) "We could soon see some good gains in AGN."

Dr. Andre Uddin, Research Capital Corporation (12/6/21) "AGN's risk/reward profile is attractive."

Stem Holdings Inc.

Joseph Gomes, Noble Capital Markets (10/27/21) "STEM entered into a letter of intent to acquire Colorado Harvest Co."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (10/19/21) "VIV signed an agreement to supply 6.3 tons of OxC-beta to a customer."

Stem Holdings Inc.

Joseph Gomes, Noble Capital Markets (10/13/21) "STEM launched the Budee Cannabis Delivery app in Apple's App Store."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (10/7/21) "VIV entered an eight-year distribution agreement with AB Vista."

Joseph Gomes, Noble Capital Markets (9/30/21) "VIV's pipeline continues to expand."

Stem Holdings Inc.

Joseph Gomes, Noble Capital Markets (9/21/21) "STEM acquired a cannabis extraction company and two dispensaries."

Joseph Gomes, Noble Capital Markets (9/21/21) "STEM received a license to open a distribution hub in Mendota, Calif."

Awakn Life Sciences Corp.

Jason McCarthy, Maxim Group (9/1/21) "We initiate coverage on AWKNF with a Buy rating."

Reliq Health Technologies Inc.

Clive Maund, CliveMaund.com (8/29/21) "RTG's vigorous uptrend is probably targeting the CA$1.30–1.40 area."

Stem Holdings Inc.

Joseph Gomes, Noble Capital Markets (8/18/21) "STEM continued to build momentum during Q3 FY21."

Algernon Pharmaceuticals Inc.

Dr. Andre Uddin, Research Capital Corporation (8/4/21) "AGN is switching focus to the IPF/chronic cough indication."

Stem Holdings Inc.

Jonathan DeCourcey, Viridian Capital Advisors (6/24/21) "STEM will benefit from strong wholesale sales trends."

Avivagen Inc.

David Bautz, Zacks Small-Cap Research (6/14/21) "We are very encouraged how VIV continues to expand its customer base and increase the size and frequency of orders for OxC-beta Livestock."

Joseph Gomes, Noble Capital Markets (6/4/21) "Momentum continues to build for VIV."

Stem Holdings Inc.

Joseph Gomes, Noble Capital Markets (5/24/21) "STEM's Q2 FY21 gross revenue was $12.4M, net revenue was $10.5M."

Algernon Pharmaceuticals Inc.

Sam Riches, Weekend Dispensary (5/22/21) "AGN received positive FDA feedback on its planned Phase 1 trial."

Dr. Andre Uddin, Research Capital Corporation (5/10/21) "AGN requested a meeting with the FDA to discuss advancing ifenprodil."

Stem Holdings Inc.

Joseph Gomes, Noble Capital Markets (5/5/21) "STEM's expansion is positive and in line with company growth plans."

Avivagen Inc.

Joseph Gomes, Noble Capital Markets (5/4/21) "We believe VIV is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."

Joseph Gomes, Noble Capital Markets (4/26/21) "VIV received a purchase order for 4.4 mt of OxC-beta Livestock."

David Bautz, Zacks Small-Cap Research (3/8/21) "VIV's orders received thus far for 2021 exceed last year's totals."

Joseph Gomes, Noble Capital Markets (3/5/21) "Another manuscript on benefits of VIV's OxC-beta will be published."

Joseph Gomes, Noble Capital Markets (3/1/21) "We are initiating research coverage on VIV with an Outperform rating."